Hie-Won Hann1, Surbhi Jain2, Grace Park1, Jamin D Steffen2, Wei Song2, Ying-Hsiu Su3. 1. Liver Disease Prevention Center, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA. 2. JBS Science, Inc., Doylestown, PA 18902, USA. 3. The Baruch S. Blumberg Institute, Doylestown, PA 18902, USA.
Abstract
AIM: This study aimed to explore the potential of detecting hepatocellular carcinoma (HCC)-associated DNA markers, TP53 249T mutations and aberrant methylation of RASSF1A and GSTP1 genes, for monitoring HCC recurrence. HCC remains a leading cause of death worldwide, with one of the fastest growing incidence rates in the US. While treatment options are available and new ones emerging, there remains a poor prognosis of this disease mostly due to its late diagnosis and high recurrence rate. Although there are no specific guidelines addressing how HCC recurrence should be monitored, recurrence is usually monitored by serum-alpha fetal protein and imaging methods such as magnetic resonance imaging (MRI). However, early detection of recurrent HCC remains limited, particularly at the site of treated lesion. METHODS: Here, the authors followed 10 patients that were treated for a primary HCC, and monitored for months or years later. At these follow-up visits, urine was collected and tested retrospectively for 3 DNA biomarkers that associate with HCC development. RESULTS: This 10-patient study compared detection of urine DNA markers with MRI for monitoring HCC recurrence. Five patients were confirmed by MRI for recurrence, and all 5 had detectable DNA biomarkers up to 9 months before recurrence confirmation by MRI. CONCLUSION: Overall, this suggests that detection of HCC-associated DNA markers in urine could provide a promising tool to complement detection of recurrent HCC by imaging.
AIM: This study aimed to explore the potential of detecting hepatocellular carcinoma (HCC)-associated DNA markers, TP53 249T mutations and aberrant methylation of RASSF1A and GSTP1 genes, for monitoring HCC recurrence. HCC remains a leading cause of death worldwide, with one of the fastest growing incidence rates in the US. While treatment options are available and new ones emerging, there remains a poor prognosis of this disease mostly due to its late diagnosis and high recurrence rate. Although there are no specific guidelines addressing how HCC recurrence should be monitored, recurrence is usually monitored by serum-alpha fetal protein and imaging methods such as magnetic resonance imaging (MRI). However, early detection of recurrent HCC remains limited, particularly at the site of treated lesion. METHODS: Here, the authors followed 10 patients that were treated for a primary HCC, and monitored for months or years later. At these follow-up visits, urine was collected and tested retrospectively for 3 DNA biomarkers that associate with HCC development. RESULTS: This 10-patient study compared detection of urine DNA markers with MRI for monitoring HCC recurrence. Five patients were confirmed by MRI for recurrence, and all 5 had detectable DNA biomarkers up to 9 months before recurrence confirmation by MRI. CONCLUSION: Overall, this suggests that detection of HCC-associated DNA markers in urine could provide a promising tool to complement detection of recurrent HCC by imaging.
Authors: Nazario Portolani; Arianna Coniglio; Sara Ghidoni; Mara Giovanelli; Anna Benetti; Guido Alberto Massimo Tiberio; Stefano Maria Giulini Journal: Ann Surg Date: 2006-02 Impact factor: 12.969
Authors: Surbhi Jain; Lijia Xie; Batbold Boldbaatar; Selena Y Lin; James P Hamilton; Stephen J Meltzer; Shun-Hua Chen; Chi-Tan Hu; Timothy M Block; Wei Song; Ying-Hsiu Su Journal: Hepatol Res Date: 2014-12-09 Impact factor: 4.288
Authors: Benjamin P Song; Surbhi Jain; Selena Y Lin; Quan Chen; Timothy M Block; Wei Song; Dean E Brenner; Ying-Hsiu Su Journal: J Mol Diagn Date: 2012-01-16 Impact factor: 5.568
Authors: Beom Kyung Kim; Jun Yong Park; Do Young Kim; Ja Kyung Kim; Kyung Sik Kim; Jin Sub Choi; Byung Soo Moon; Kwang Hyub Han; Chae Yoon Chon; Young Myoung Moon; Sang Hoon Ahn Journal: Liver Int Date: 2007-11-19 Impact factor: 5.828
Authors: Ying-Hsiu Su; Janet Song; Zhili Wang; Xiao-He Wang; Mengjun Wang; Dean E Brenner; Timothy M Block Journal: Ann N Y Acad Sci Date: 2008-08 Impact factor: 5.691
Authors: Hie-Won Hann; Robert Coben; Daniel Brown; Laurence Needleman; Ernest Rosato; Albert Min; Richard S Hann; Kyong Bin Park; Stephen Dunn; Anthony J DiMarino Journal: Cancer Med Date: 2014-02-12 Impact factor: 4.452
Authors: Caitlin M Stewart; Prachi D Kothari; Florent Mouliere; Richard Mair; Saira Somnay; Ryma Benayed; Ahmet Zehir; Britta Weigelt; Sarah-Jane Dawson; Maria E Arcila; Michael F Berger; Dana Wy Tsui Journal: J Pathol Date: 2018-03-12 Impact factor: 7.996